Comparison of Tolvaptan treatment and conventional treatment in elderly acute heart failure.

Comparison of Tolvaptan treatment and conventional treatment in elderly acute heart failure. - Comparison of Tolvaptan treatment and conventional treatment in elderly acute heart failure.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028039

Enrollment

Registered

2017-07-03

Start date

2017-02-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute decompensated heart failure

Interventions

Conventional therapy group Tolvaptan add-on therapy group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Acute decompensated heart failure patients diagnosed by Framingham criteria. 2.Patients who are able to take oral medications 3.age 76 over 4.Partients hospitalized for over time visits

Exclusion criteria

Exclusion criteria: 1.Under 75 2.Hypersensitivity for Tolvaptan or Mozavaptan. 3.Anuria 4.Insensitivity to thurst of difficulty in water in take. 5.Patients who already have tolvaptan at entry. 6.Severe coronary arterydisease and cerebrovascular disease. 7.Severe renal failure 8.Hypernatremia(serum Na>146mEq/L)and(serum Na<125mEq/L). 9.Hyperkalemia(serum K>5.5mEq/L)and(serum K<3.0mEq/L). 10.Chronic hepatitis Liver dysfunction(pharmacological etc.). 11.Hepatic encephalopathy. 12.Any conditions inappropriate to this trial deemed by the investigator.

Design outcomes

Primary

Measure	Time frame
Changes in circulating plasma volume by IVC.	—

Countries

Japan

Contacts

Public ContactYasushi Takizawa

Iiyama redcross hospital Division of pharmacy

asha_trial@yahoo.co.jp0269-62-4195

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026